RayKnowChina Research Map
Shortlist

ChongqingChongqing Medical University

Second Affiliated Hospital of Chongqing Medical University

重庆医科大学附属第二医院

Listed for 27 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Second Affiliated Hospital of Chongqing Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌10 papers led
  2. Hepatocellular carcinoma肝细胞癌108 papers led
  3. Stomach cancer胃癌23 papers led
  4. Lung cancer肺癌67 papers led1 open trial led
  5. Pancreatic cancer胰腺癌23 papers led
  6. Breast cancer乳腺癌43 papers led
  7. Glioma胶质瘤18 papers led
  8. Retinoblastoma视网膜母细胞瘤5 papers led
  9. Osteosarcoma骨肉瘤7 papers led
  10. Gastrointestinal stromal tumour胃肠道间质瘤4 papers led
  11. Neuroblastoma神经母细胞瘤2 papers led
  12. Ewing sarcoma尤文肉瘤1 paper led
  13. Aplastic anaemia再生障碍性贫血2 papers led
  14. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  15. Haemophilia A血友病 A1 paper led
  16. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜2 papers led
  17. Fanconi anaemia范可尼贫血1 paper led
  18. Coronary heart disease冠心病10 papers led
  19. Congenital heart disease先天性心脏病4 papers led
  20. Takayasu arteritis大动脉炎1 paper led
  21. Hepatic echinococcosis肝包虫病1 paper led
  22. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  23. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  24. Behçet disease白塞病1 paper led
  25. IgA nephropathyIgA 肾病1 paper led
  26. Niemann–Pick disease type C尼曼-匹克病 C 型1 paper led
  27. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Chordoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Lymphoma, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Scoliosis, Anti-NMDA receptor encephalitis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 10 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 4420242025: 332025

7 hospitals in Chongqing for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & AINeoadjuvant & combined treatmentImmunotherapy
Departments in papersRadiology / nuclear medicineGastroenterology / hepatology
Papers it led10
  1. MRI based fractal analysis of esophageal squamous cell carcinoma to preoperatively predict lymphnode metastasis.2026European journal of radiology
  2. Preoperative identification of small metastatic lymph nodes in esophageal squamous cell carcinoma using CT radiomics of lymph nodes.2025Abdominal radiology (New York)
  3. Adjuvant immunotherapy in esophageal squamous cell carcinoma after radiotherapy: retrospective multicentric survival analysis.2025Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  4. Transcription factor SPI1 exacerbates the malignant progression of esophageal squamous cell carcinoma byactivating LAMA3 expression.2025General physiology and biophysics
  5. Contrast-enhanced CT radiomics features to preoperatively identify differences between tumor and proximal tumor-adjacent and tumor-distant tissues of resectable esophageal squamous cell carcinoma.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  6. Baseline CT radiomics features to predict pathological complete response of advanced esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy using paclitaxel and cisplatin.2024European journal of radiology
  7. Preoperative CT radiomics of esophageal squamous cell carcinoma and lymph node to predict nodal disease with a high diagnostic capability.2024European journal of radiologyRCT
  8. Association between sulfur microbial diet and the risk of esophageal cancer: a prospective cohort study in 101,752 American adults.2024Nutrition journalFree full text
  9. Fusobacterium nucleatum promotes the early occurrence of esophageal cancer through upregulation of IL-32/PRTN3 expression.2023Cancer scienceFree full text
  10. Toxic epidermal necrolysis during camrelizumab treatment for esophageal squamous cell carcinoma.2022Contact dermatitis
More papers found outside PubMed (not counted)1
  1. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 108 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
108
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 212120212022: 161620222023: 272720232024: 222220242025: 18182025

5 hospitals in Chongqing for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-12
    Posted
    Registry
    NCT07866612

    Age 18 years to 80 years (registered criteria)

    Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionHepatitis B & cirrhosis
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led108
  1. O-GlcNAcylation of DDX46 promotes hepatocellular carcinoma progression by activating the PI3K/Akt signaling pathway.2026Biochimica et biophysica acta. Molecular cell research
  2. MASTL Promotes Hepatocellular Carcinoma Progression and Paclitaxel Resistance Through Mitotic Catastrophe.2026Cancer scienceFree full text
  3. Acetyl-coenzyme A synthetase 2-mediated acetyl-coenzyme A accumulation promotes mitophagy and tumor growth via increased H3K27ac in hepatitis B virus-related hepatocellular carcinoma.2026Clinical and molecular hepatologyFree full text
  4. Contrast-enhanced MRI-based multi-parameter habitats radiomics models to predict early recurrence in early-stage hepatocellular carcinoma following curative resection.2026European journal of radiology
  5. RPL6 Interacts with HMGCS1 to Stabilize HIF-1α by Promoting Cholesterol Production in Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  6. Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  7. Dietary monounsaturated fatty acid facilitates lipid droplet turnover through chaperone HSP90A-mediated lysosomal degradation of PLIN2 in hepatocellular carcinoma.2025AutophagyFree full text
  8. Hypoxia reduces SLC27A5 to promote hepatocellular carcinoma proliferation by repressing HNF4A.2025Biochimica et biophysica acta. Molecular cell research
  9. SNRPA promotes hepatocellular carcinoma proliferation and lenvatinib resistance via B7-H6-STAT3/AKT axis by facilitating B7-H6 pre-mRNA maturation.2025Bioscience trends
  10. SPOP Suppresses Hepatocellular Carcinoma Growth and Metastasis by Ubiquitination and Proteasomal Degradation of TRAF6.2025Cancer scienceFree full text
  11. GFAT1 promotes the progression of hepatocellular carcinoma via enhancing the O-GlcNAcylation of VEZF1.2025Cell death & diseaseFree full text
  12. O-GlcNAcylation of METTL3 drives hepatocellular carcinoma progression by upregulating MCM10 expression in an m6A-IGF2BP3-dependent manner.2025Cell death & diseaseFree full text
  13. LncRNA DERCNC in Hepatocellular Carcinoma with Cirrhosis Aggravates Tumor Proliferation by Targeting SOX9.2025Current cancer drug targets
  14. Predicting postresection outcomes in solitary small hepatocellular carcinoma via pretreatment MR imaging features: subgroup analysis according to alpha-fetoprotein expression.2025European radiology
  15. Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy.2025Frontiers in cellular and infection microbiologyFree full text
  16. Integrating bioinformatics and experimental validation to reveal a novel VRK score as a prognostic and therapeutic biomarker in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  17. Immunoregulatory function and anticancer effects of Polygonatum sibiricum polysaccharides against hepatic carcinoma via macrophage phenotype modulation.2025International journal of biological macromolecules
  18. Neutrophil-macrophage crosstalk via NETs-IL-17/VEGF/S100A9 axis promotes hepatocellular carcinoma progression.2025Journal of experimental & clinical cancer research : CRFree full text
  19. Diagnostic value of TAP, PIVKA-II, and AFP in hepatocellular carcinoma and their prognostic value for patients treated with transarterial chemoembolization.2025Laboratory medicine
  20. Phosphoglycerate dehydrogenase stabilizes protein kinase C delta type mRNA to promote hepatocellular carcinoma progression.2025Signal transduction and targeted therapyFree full text
  21. Biomimetic Dual-Engine Nanodisruptor Degrades Extracellular Matrix and Hijacks TAM2 to Unlock Deep Immune Infiltration in HCC.2025Small (Weinheim an der Bergstrasse, Germany)
  22. A nomogram based on PNI and preoperative TACE can predict overall survival in patients with larger than 2 cm HCC after hepatectomy.2025Updates in surgery
  23. Metabolic Enzyme SLC27A5 Regulates PIP4K2A pre-mRNA Splicing as a Noncanonical Mechanism to Suppress Hepatocellular Carcinoma Metastasis.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  24. Loss of LRP1 Promotes Hepatocellular Carcinoma Progression via UFL1-Mediated Activation of NF-κB Signaling.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  25. Loss of Carbamoyl Phosphate Synthetase 1 Potentiates Hepatocellular Carcinoma Metastasis by Reducing Aspartate Level.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  26. Impact of preoperative transcatheter arterial chemoembolization (TACE) on postoperative long-term survival in patients with nonsmall hepatocellular carcinoma: a propensity score matching analysis.2024BMC cancerFree full text
  27. Systemic loss of CD36 aggravates NAFLD-related HCC through MEK1/2-ERK1/2 signaling pathway.2024Biochemical and biophysical research communications
  28. Analysis of clinical significance and molecular characteristics of methionine metabolism and macrophage-related patterns in hepatocellular carcinoma based on machine learning.2024Cancer biomarkers : section A of Disease markersFree full text
  29. PD-L1+ neutrophils induced NETs in malignant ascites is a potential biomarker in HCC.2024Cancer immunology, immunotherapy : CIIFree full text
  30. Inhibiting cholesterol de novo synthesis promotes hepatocellular carcinoma progression by upregulating prostaglandin E synthase 2-mediated arachidonic acid metabolism under high fatty acid conditions.2024Cancer scienceFree full text
  31. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Hepatocellular Carcinoma Treated with Conventional Transcatheter Arterial Chemoembolization: A Propensity Score Matched Analysis.2024Cardiovascular and interventional radiology
  32. m6A demethylation of FOSL1 mRNA protects hepatoma cells against necrosis under glucose deprivation.2024Cell death and differentiationFree full text
  33. Non-canonical function of PHGDH promotes HCC metastasis by interacting with METTL3.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  34. Development and validation of a model for predicting who can benefit from multiple TACE in HCC patients.2024Clinical and experimental medicineFree full text
  35. Prediction of microvascular invasion and pathological differentiation of hepatocellular carcinoma based on a deep learning model.2024European journal of radiology
  36. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B: still needs further discussion.2024Gut
  37. Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk-A multinational cohort study of HBeAg-positive patients.2024Hepatology (Baltimore, Md.)
  38. Immunomodulatory effects of Fructus corni acidic polysaccharide and its selenium nanoparticles composites in hepatocellular carcinoma.2024International journal of biological macromolecules
  39. Anti-hepatoma immunotherapy of Pholiota adiposa polysaccharide-coated selenium nanoparticles by reversing M2-like tumor-associated macrophage polarization.2024International journal of biological macromolecules
  40. Smart responsive Fe/Mn nanovaccine triggers liver cancer immunotherapy via pyroptosis and pyroptosis-boosted cGAS-STING activation.2024Journal of nanobiotechnologyFree full text
  41. Mito-LND and (E)-Akt inhibitor-IV: novel compounds inducing endoplasmic reticulum stress and ROS accumulation against hepatocellular carcinoma.2024Journal of translational medicineFree full text
  42. O-GlcNAcylation of E3 ubiquitin ligase SKP2 promotes hepatocellular carcinoma proliferation.2024Oncogene
  43. Combination of bulk RNA and single-cell sequencing unveils PANoptosis-related immunological ecology hallmarks and classification for clinical decision-making in hepatocellular carcinoma.2024Scientific reportsFree full text
  44. Metadherin promotes stem cell phenotypes and correlated with immune infiltration in hepatocellular carcinoma.2024World journal of gastroenterologyFree full text
  45. Peroxisomal trans-2-enoyl-CoA inhibits proliferation, migration and invasion of hepatocellular carcinoma cells.2023Acta histochemica
  46. P53/miR-34a/SIRT1 positive feedback loop regulates the termination of liver regeneration.2023AgingFree full text
  47. Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (L-ALPPS) After Conversion Therapy for BCLC-B Hepatocellular Carcinoma: A Video Article.2023Annals of surgical oncology
  48. Transradial versus transfemoral approach for TACE: a retrospective study.2023BMC gastroenterologyFree full text
  49. Elevated neutrophil extracellular traps by HBV-mediated S100A9-TLR4/RAGE-ROS cascade facilitate the growth and metastasis of hepatocellular carcinoma.2023Cancer communications (London, England)Free full text
  50. Transcriptional regulation of NDUFA4L2 by NFIB induces sorafenib resistance by decreasing reactive oxygen species in hepatocellular carcinoma.2023Cancer scienceFree full text
  51. Programmed death ligand 1 regulates epithelial-mesenchymal transition and cancer stem cell phenotypes in hepatocellular carcinoma through the serum and glucocorticoid kinase 2/β-catenin signaling pathway.2023Cancer scienceFree full text
  52. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.2023Cell death & diseaseFree full text
  53. High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate.2023Cell metabolism
  54. Circulating sNinj1 as a novel predictor of prognosis and severity in hepatocellular carcinoma.2023Clinica chimica acta; international journal of clinical chemistry
  55. Identification of a novel plasma metabolite panel as diagnostic biomarker for hepatocellular carcinoma.2023Clinica chimica acta; international journal of clinical chemistry
  56. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis.2023Current oncology (Toronto, Ont.)Free full text
  57. Deep learning-assisted LI-RADS grading and distinguishing hepatocellular carcinoma (HCC) from non-HCC based on multiphase CT: a two-center study.2023European radiology
  58. Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre real-world analysis with propensity score matching.2023Frontiers in immunologyFree full text
  59. Laparoscopic liver resection for hepatocellular carcinoma complicated with significant portal hypertension: A propensity score-matched survival analysis.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  60. Circular RNA hsa_circ_0000519 contributes to angiogenesis and tumor progression in hepatocellular carcinoma through the miR-1296/E2F7 axis.2023Human cell
  61. Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors.2023Human vaccines & immunotherapeuticsFree full text
  62. High-intensity focused ultrasound versus transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.2023International journal of radiation biology
  63. Integrative analysis reveals that SLC38A1 promotes hepatocellular carcinoma development via PI3K/AKT/mTOR signaling via glutamine mediated energy metabolism.2023Journal of cancer research and clinical oncologyFree full text
  64. A novel nomogram based on the hematological prognosis risk scoring system can predict the overall survival of patients with hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  65. VEGF/Nrp1/HIF-1α promotes proliferation of hepatocellular carcinoma through a positive feedback loop.2023Medical oncology (Northwood, London, England)
  66. Lysyl hydroxylase LH1 promotes confined migration and metastasis of cancer cells by stabilizing Septin2 to enhance actin network.2023Molecular cancerFree full text
  67. O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma.2023Oncogene
  68. Liver fibrosis-derived exosomal miR-106a-5p facilitates the malignancy by targeting SAMD12 and CADM2 in hepatocellular carcinoma.2023PloS oneFree full text
  69. ANXA10 is a prognostic biomarker and suppressor of hepatocellular carcinoma: a bioinformatics analysis and experimental validation.2023Scientific reportsFree full text
  70. O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner.2023Signal transduction and targeted therapyFree full text
  71. Identification of a diketopiperazine-based O-GlcNAc transferase inhibitor sensitizing hepatocellular carcinoma to CDK9 inhibition.2023The FEBS journal
  72. A theranostic metallodrug modulates immunovascular crosstalk to combat immunosuppressive liver cancer.2022Acta biomaterialia
  73. Identification of alanine aminotransferase 1 interaction network via iTRAQ-based proteomics in alternating migration, invasion, proliferation and apoptosis of HepG2 cells.2022AgingFree full text
  74. LINC02154 promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing SPC24 promoter activity and activating the PI3K-AKT signaling pathway.2022Cellular oncology (Dordrecht, Netherlands)Free full text
  75. Dysregulated glucuronic acid metabolism exacerbates hepatocellular carcinoma progression and metastasis through the TGFβ signalling pathway.2022Clinical and translational medicineFree full text
  76. circKCNN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regulating miR-520c-3p/methyl-DNA-binding domain protein 2 axis.2022Clinical and translational medicineFree full text
  77. Green synthesized gold nanoparticles from Pseudobulbus Cremastrae seu Pleiones show efficacy against hepatic carcinoma potentially through immunoregulation.2022Drug deliveryFree full text
  78. PCDH17 is regulated by methylation of DNMT3B and affects the malignant biological behavior of HCC through EMT.2022Experimental cell research
  79. High platelet count predicts poor prognosis in HCC patients undergoing TACE: a propensity score-matched analysis.2022Expert review of gastroenterology & hepatology
  80. ALKBH5/MAP3K8 axis regulates PD-L1+ macrophage infiltration and promotes hepatocellular carcinoma progression.2022International journal of biological sciencesFree full text
  81. Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective study.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  82. Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma.2022Journal of experimental & clinical cancer research : CRFree full text
  83. Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma.2022Liver international : official journal of the International Association for the Study of the LiverFree full text
  84. Identification of G6PC as a potential prognostic biomarker in hepatocellular carcinoma based on bioinformatics analysis.2022MedicineFree full text
  85. miR-550a-5p promotes the proliferation and migration of hepatocellular carcinoma by targeting GNE via the Wnt/β-catenin signaling pathway.2022Neoplasma
  86. Salivary orosomucoid 1 as a biomarker of hepatitis B associated hepatocellular carcinoma.2022Scientific reportsFree full text
  87. CK1α upregulates the IFNAR1 expression to prompt the anti-HBV effect of type I IFN in hepatoma carcinoma cells.2022Virologica SinicaFree full text
  88. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.2021AgingFree full text
  89. Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway.2021Asian Pacific journal of cancer prevention : APJCPFree full text
  90. Identification and Validation of a Prognostic Model Based on Three Autophagy-Related Genes in Hepatocellular Carcinoma.2021BioMed research internationalFree full text
  91. The role of CD133 in hepatocellular carcinoma.2021Cancer biology & therapyFree full text
  92. Systematic analysis of immune-related genes based on a combination of multiple databases to build a diagnostic and a prognostic risk model for hepatocellular carcinoma.2021Cancer immunology, immunotherapy : CIIFree full text
  93. Normal tissue adjacent to tumor expression profile analysis developed and validated a prognostic model based on Hippo-related genes in hepatocellular carcinoma.2021Cancer medicineFree full text
  94. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.2021Cell death & diseaseFree full text
  95. Circular RNA hsa_circ_101555 promotes hepatocellular carcinoma cell proliferation and migration by sponging miR-145-5p and regulating CDCA3 expression.2021Cell death & diseaseFree full text
  96. The fatty acid receptor CD36 promotes HCC progression through activating Src/PI3K/AKT axis-dependent aerobic glycolysis.2021Cell death & diseaseFree full text
  97. GASC1 promotes hepatocellular carcinoma progression by inhibiting the degradation of ROCK2.2021Cell death & diseaseFree full text
  98. Ubiquitin-specific protease 2a promotes hepatocellular carcinoma progression via deubiquitination and stabilization of RAB1A.2021Cellular oncology (Dordrecht, Netherlands)Free full text
  99. Epigenetic silencing of GCH1promotes hepatocellular carcinoma growth by activating superoxide anion-mediated ASK1/p38 signaling via inhibiting tetrahydrobiopterin de novo biosynthesis.2021Free radical biology & medicine
  100. A Web-Based Prediction Model for Cancer-Specific Survival of Elderly Patients With Early Hepatocellular Carcinoma: A Study Based on SEER Database.2021Frontiers in public healthRCTFree full text
  101. iRGD Peptide-Mediated Liposomal Nanoparticles with Photoacoustic/Ultrasound Dual-Modality Imaging for Precision Theranostics Against Hepatocellular Carcinoma.2021International journal of nanomedicineFree full text
  102. RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.2021Journal of gastroenterology and hepatology
  103. C2orf40 inhibits hepatocellular carcinoma through interaction with UBR5.2021Journal of gastroenterology and hepatology
  104. Bioinformatics analysis of constructing a HCV-related hepatocellular carcinoma miRNA-mRNA regulation network.2021MedicineFree full text
  105. Identification and validation of EPHX2 as a prognostic biomarker in hepatocellular carcinoma.2021Molecular medicine reportsFree full text
  106. O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis.2021OncogeneFree full text
  107. TACE Combined with HIFU Versus Surgical Resection for Single Hepatocellular Carcinoma with Child-Pugh B Cirrhosis in Overall Survival and Progression-Free Survival: A Retrospective Study.2021Technology in cancer research & treatmentFree full text
  108. Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization.2021World journal of gastroenterologyFree full text
Chinese-language papers (not in the count)7
  1. [Study of a nomogram model of gadoxetate disodium-enhanced magnetic resonance imaging for the preoperative diagnosis of proliferative hepatocellular carcinoma and its value].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Comparative study of ultra-high field diffusion-weighted MRI imaging between hepatocellular carcinoma and paracancerous, distant cancerous, and background liver tissues].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  3. [Research progress and prospects of the application of radiographic imaging in the precise diagnosis and treatment of hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  4. [Study on F9 gene expression downregulation and its clinical value in hepatocellular carcinoma].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  5. [Research progress of compound injection of traditional Chinese medicine in the treatment of liver cancer].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  6. [Research status and challenges of low-level viremia in chronic hepatitis B].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  7. [Treatment and prevention of bile duct injury in hepatocellular carcinoma after transarterial chemoembolization].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status8
  1. Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular CarcinomaStatus unknownNCT05670561Lead sponsorPhase 4Start 2023-01
  2. Auxiliary Diagnosis of Liver Nodules Using cfDNA Whole-genome SignaturesStatus unknownNCT05393102Lead sponsorStart 2022-05
  3. Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular CarcinomaStatus unknownNCT05416073Lead sponsorPhase 4Start 2022-06
  4. Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic PlatformStatus unknownNCT05242237Lead sponsorStart 2021-12
  5. Effect of Nutritional Indices on the Prognosis of HCC PatientsCompletedNCT05635279Lead (inferred)Start 2022-11
  6. Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular CarcinomaNot yet recruitingNCT07866612Study siteN/AStart 2026-12
  7. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  8. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 23 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
23
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 5520222023: 7720232024: 5520242025: 332025

6 hospitals in Chongqing for stomach cancer211 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEarly detection & endoscopyPeritoneal spread & advanced diseaseImaging & AI
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineMedical oncology
Papers it led23
  1. Association between the red blood cell distribution width-to-albumin ratio and risk of colorectal and gastric cancers: a cross-sectional study using NHANES 2005-2018.2025BMC gastroenterologyFree full text
  2. Early-onset gastric cancer global burden profile, trends, and contributors.2025Cancer biology & medicineFree full text
  3. Gastric Adenocarcinoma Resembling Submucosal Tumor: A Case Report.2025The American journal of case reportsFree full text
  4. A novel combined therapeutic strategy of Nano-EN-IR@Lip mediated photothermal therapy and stem cell inhibition for gastric cancer.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  5. RHBDD1 Promotes the Growth and Stemness Characteristics of Gastric Cancer Cells by Activating Wnt/β-catenin Signaling Pathway.2024Current stem cell research & therapy
  6. VEPH1 suppresses the progression of gastric cancer by regulating the Hippo-YAP signalling pathway.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  7. CT radiomics based on the peritumoral adipose region of gastric adenocarcinoma for preoperative prediction of lymph node metastasis.2024European journal of radiology
  8. Exploring the mediating role of blood metabolites in the relationship between gut microbiota and gastric cancer risk: a Mendelian randomization study.2024Frontiers in cellular and infection microbiologyFree full text
  9. Aquaporins in Digestive System.2023Advances in experimental medicine and biology
  10. The GLI2/CDH6 axis enhances migration, invasion and mitochondrial fission of stomach adenocarcinoma cells.2023Biochemical and biophysical research communications
  11. Balloon-assisted technique for endoscopic en bloc retrieval of a large gastric gastrointestinal stromal tumor specimen.2023EndoscopyFree full text
  12. Three-arm endoscopic mucosal resection for gastric adenocarcinoma of fundic gland type.2023EndoscopyFree full text
  13. Integration of endoscopic screening, magnification, and resection for early gastric cancer: advantages of underwater EMR (with video).2023Gastrointestinal endoscopy
  14. Metabolic-associated fatty liver disease and risk of esophagogastric cancer: a systematic review and meta-analysis.2023Japanese journal of clinical oncology
  15. Dimethyladenosine Transferase 1 Homolog Promotes Human Gastric Carcinoma Cell Proliferation and Inhibits Apoptosis via the AKT Pathway.2023The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  16. Establishment of a 10-gene prognostic model for gastric cancer based on the tumor immune microenvironment.2022Analytical biochemistry
  17. Comprehensive Analysis of the Immune Implication of AKAP12 in Stomach Adenocarcinoma.2022Computational and mathematical methods in medicineFree full text
  18. Double-band ligation-assisted endoscopic submucosal resection for type 1 gastric neuroendocrine tumor with type A gastritis.2022Endoscopy
  19. Comprehensive analysis of the immune and prognostic implication of MASP1 in stomach adenocarcinoma.2022European review for medical and pharmacological sciences
  20. Knockdown of TRIM65 suppressed the proliferation and invasiveness of gastric cancer cells by restricting the ubiquitin degradation of PPM1A.2022Experimental cell research
  21. The transcription factor RUNX2 fuels YAP1 signaling and gastric cancer tumorigenesis.2021Cancer scienceFree full text
  22. Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report.2021MedicineFree full text
  23. LAMB1 Is Related to the T Stage and Indicates Poor Prognosis in Gastric Cancer.2021Technology in cancer research & treatmentFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Validating the Safety and Effectiveness of ENDOANGEL Upper Gastrointestinal Endoscope Image Auxiliary Diagnostic SoftwareStatus unknownNCT05470452Lead sponsorN/AStart 2021-07
  2. HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk PatientsStatus unknownNCT05510388Study siteN/AStart 2022-09
  3. Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Gastric Cancer PatientsStatus unknownNCT06606912Study siteStart 2012-01

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 67 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
67
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 4420212022: 141420222023: 141420232024: 121220242025: 21212025

9 hospitals in Chongqing for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Functional Lung Avoidance Radiotherapy Guided by 4DCT Pulmonary Ventilation Function Imaging: A Prospective Single-arm Clinical Study
    Phase
    N/A
    Started
    2025-10
    Posted
    Registry
    NCT07339644

    Age 18 years to 85 years (registered criteria)

    Led by Second Affiliated Hospital of Chongqing Medical UniversityChongqing

  2. Recruiting
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07416474

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai

  3. Recruiting
    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06890598

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an

  4. Recruiting
    Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06121505

    Age 18 years to 75 years (registered criteria)

    Led by West China Hospital; 4 listed hospitals as study sitesChengdu, Chongqing, Nanchong, Wuhan

  5. Recruiting
    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06300177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  6. Not yet recruiting
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT05767892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine
Papers it led67
  1. Identification of a novel RET::FOXJ3 fusion in lung adenocarcinoma associated with lack of response to pralsetinib.2026Cancer letters
  2. Confined electrochemiluminescence at single tissue sections for enhanced imaging of surface antigens.2026Talanta
  3. RPL6 Interacts with HMGCS1 to Stabilize HIF-1α by Promoting Cholesterol Production in Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Gene mutation in cancer patients with diabetes: a real-world retrospective cohort study.2025BMC cancerFree full text
  5. Integration of intratumoral and peritumoral CT radiomic features with machine learning algorithms for predicting induction therapy response in locally advanced non-small cell lung cancer.2025BMC cancerFree full text
  6. Characterization of the genomic landscape in liver oligometastatic NSCLC.2025BMC cancerFree full text
  7. The association between energy-adjusted dietary inflammatory index (E-DII) and lung cancer in 101,755 participants aged 55 years and above: a large prospective cohort.2025BMC public healthFree full text
  8. Pathomics-based machine learning models for optimizing LungPro navigational bronchoscopy in peripheral lung lesion diagnosis: a retrospective study.2025Biomedical engineering onlineFree full text
  9. NFATc4 Promotes Lung Adenocarcinoma Progression via the CCNB1/CDK1 Pathway and Is a Potential Prognostic Biomarker.2025Cancer scienceFree full text
  10. Survival outcomes of upfront versus delayed craniocerebral radiotherapy in EGFR-mutant NSCLC patients treated with third-generation EGFR-TKIs.2025Clinical & experimental metastasis
  11. Efficacy and safety analysis of atezolizumab continuation beyond progression in extensive-stage small cell lung cancer.2025Clinical and experimental medicineFree full text
  12. Associations between postoperative pulmonary interventions based on enhanced recovery programs and outcomes in patients with lung cancer: A retrospective propensity score matching study.2025European journal of oncology nursing : the official journal of European Oncology Nursing Society
  13. A liver CT based nomogram to preoperatively predict lung metastasis secondary to hepatic alveolar echinococcosis.2025European journal of radiology
  14. ACSS3 promotes the tumorigenesis of non-small cell lung cancer via suppressing p53-mediated ferroptosis.2025Experimental cell research
  15. Identification of a ubiquitin-binding domain protein, CD2AP, in predicting the prognosis and treatment of lung adenocarcinoma.2025Frontiers in immunologyFree full text
  16. Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.2025Frontiers in immunologyFree full text
  17. Synthesis of Epimedium extract selenium nanoparticles and evaluation their efficacy against lung cancer.2025General physiology and biophysics
  18. Innate immune dynamics in the context of multisite EGFR mutations in lung adenocarcinoma.2025Genes and immunity
  19. Protein arginine methyltransferase 7-mediated arginine mono-methylation stabilizes SRY-box transcription factor 9 to promote non-small cell lung cancer progression.2025Molecular biomedicineFree full text
  20. Effects of EGFR-TKIs combined with intracranial radiotherapy in EGFR-mutant non-small cell lung cancer patients with brain metastases: a retrospective multi-institutional analysis.2025Radiation oncology (London, England)Free full text
  21. A cohort study on the association of dietary inflammatory index and a posteriori dietary patterns with lung cancer risk.2025Scientific reportsFree full text
  22. Circulating gamma-glutamyl transpeptidase, systemic inflammation biomarkers and risk of lung cancer in the UK biobank prospective cohort study.2025Scientific reportsFree full text
  23. Clinical benefits of the 5th intercostal incision in uniportal VATS for female patients.2025Scientific reportsFree full text
  24. Development and Validation of a Machine Learning-Based Model Using CT Radiomics for Predicting Immune Checkpoint Inhibitor-related Pneumonitis in Patients With NSCLC Receiving Anti-PD1 Immunotherapy: A Multicenter Retrospective CaseControl 2024Academic radiology
  25. Optimal intervention timing for craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastases.2024BMC cancerFree full text
  26. Predicting radiation pneumonitis in lung cancer using machine learning and multimodal features: a systematic review and meta-analysis of diagnostic accuracy.2024BMC cancerFree full text
  27. Elevation of LEM Domain Containing 1 Predicts Poor Prognosis of NSCLC Patients and Triggers Malignant Stemness and Invasion of NSCLC Cells by Stimulating PI3K/AKT Pathway.2024Current molecular medicine
  28. First-line combination therapy of immunotherapy plus anti-angiogenic drug for thoracic SMARCA4-deficient undifferentiated tumors in AIDS: a case report and review of the literature.2024Frontiers in immunologyFree full text
  29. The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report.2024Frontiers in immunology
  30. Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma.2024Future oncology (London, England)Free full text
  31. Morphine-induced fever: a case report and review of the literature.2024Journal of medical case reportsFree full text
  32. LIFU/MMP-2 dual-responsive release of repurposed drug disulfiram from nanodroplets for inhibiting vasculogenic mimicry and lung metastasis in triple-negative breast cancer.2024Journal of nanobiotechnologyFree full text
  33. Upregulation of M6A Reader HNRNPA2B1 Associated with Poor Prognosis and Tumor Progression in Lung Adenocarcinoma.2024Recent patents on anti-cancer drug discovery
  34. Lowering expression of Epsin-3 inhibits migration and invasion of lung adenocarcinoma cells by inhibiting the epithelial-mesenchymal transition.2024Scientific reportsFree full text
  35. Adherence to the low-fat diet pattern reduces the risk of lung cancer in American adults aged 55 years and above: a prospective cohort study.2024The journal of nutrition, health & agingFree full text
  36. Six-hour time-restricted feeding inhibits lung cancer progression and reshapes circadian metabolism.2023BMC medicineFree full text
  37. Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis.2023BMC pulmonary medicineFree full text
  38. Genomic features and its potential implication in bone oligometastatic NSCLC.2023BMC pulmonary medicineFree full text
  39. Low-fat dairy consumption and the risk of lung cancer: A large prospective cohort study.2023Cancer medicineFree full text
  40. ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinoma.2023Cancer medicineFree full text
  41. Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non-Small Cell Lung Cancer.2023Cancer research and treatmentFree full text
  42. Association between adherence to Eat-Lancet diet and incidence and mortality of lung cancer: A prospective cohort study.2023Cancer scienceFree full text
  43. Toxicity spectrum and risk factors for chemo-immunotherapy in locally advanced or metastatic lung cancer.2023Clinical and experimental immunology
  44. A nomogram predicting the outcome of gallbladder cancer patients with different target organ metastases.2023European review for medical and pharmacological sciences
  45. Efficacy of radiotherapy in combination with first-line immunotherapy and chemotherapy for advanced lung squamous cell carcinoma: a propensity score analysis.2023Frontiers in immunologyFree full text
  46. BDNF is a prognostic biomarker involved in immune infiltration of lung adenocarcinoma and is associated with brain metastasis.2023Immunology
  47. Griseofulvin Radiosensitizes Non-Small Cell Lung Cancer Cells and Activates cGAS.2023Molecular cancer therapeuticsFree full text
  48. Pan-cancer landscape of CENPO and its underlying mechanism in LUAD.2023Respiratory researchFree full text
  49. Dietary polyunsaturated fatty acids intake, air pollution, and the risk of lung cancer: A prospective study in UK biobank.2023The Science of the total environment
  50. Chordin-like 1 is a novel prognostic biomarker and correlative with immune cell infiltration in lung adenocarcinoma.2022AgingFree full text
  51. Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy.2022Angiogenesis
  52. First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis.2022Cancer immunology, immunotherapy : CIIFree full text
  53. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis.2022Cellular & molecular biology lettersFree full text
  54. Auxiliary Diagnosis of Lung Cancer with Magnetic Resonance Imaging Data under Deep Learning.2022Computational and mathematical methods in medicineFree full text
  55. PCAT19 Regulates the Proliferation and Apoptosis of Lung Cancer Cells by Inhibiting miR-25-3p via Targeting the MAP2K4 Signal Axis.2022Disease markersFree full text
  56. A Cell Differentiation Trajectory-Related Signature for Predicting the Prognosis of Lung Adenocarcinoma.2022Genetics researchFree full text
  57. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.2022Journal of cancer research and clinical oncologyFree full text
  58. Therapeutic effectiveness and safety of sequential ICIs with radiotherapy for symptomatic brain and bone metastases in NSCLC patients.2022MedicineFree full text
  59. Co-occurrence of CDKN2A/B and IFN-I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma.2022Molecular oncologyFree full text
  60. Ultrasonically Enhanced ZD2767P-Carboxypeptidase G2 Deactivates Cisplatin-Resistant Human Lung Cancer Cells.2022Oxidative medicine and cellular longevityFree full text
  61. miR-489-3p promotes malignant progression of non-small cell lung cancer through the inactivation of Wnt/β-catenin signaling pathway via regulating USP48.2022Respiratory researchFree full text
  62. Interleukin 7 inhibit autophagy via P53 regulated AMPK/mTOR signaling pathway in non-small cell lung cancer.2022Scientific reportsFree full text
  63. Prognostic nomograms for lung neuroendocrine carcinomas based on lymph node ratio: a SEER database analysis.2022The Journal of international medical researchFree full text
  64. Anti-TIF1 gamma-positive IPAF patient developed stage IVB lung squamous carcinoma in 1 year: a case report.2021BMC pulmonary medicineFree full text
  65. Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report.2021MedicineFree full text
  66. Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial.2021Neuro-oncologyRCTFree full text
  67. O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis.2021OncogeneFree full text
Chinese-language papers (not in the count)2
  1. [Risk Factors, Molecular Mechanisms, and Multimodal Early Warning Strategies 
for Immune Checkpoint Inhibitor-associated Pneumonitis in Lung Cancer].2025Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  2. [Current situation and research progress of quality of life evaluation scale in clinical application of lung cancer patients with brain metastasis].2022Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status11
  1. Functional Lung Avoidance Radiotherapy Guided by 4DCT Pulmonary Ventilation Function Imaging: A Prospective Single-arm Clinical StudyRecruitingNCT07339644Lead sponsorN/AStart 2025-10
  2. Application of 4DCT-Based Pulmonary Ventilation Imaging in Lung Cancer RadiotherapyActive, not recruitingNCT07312682Lead sponsorStart 2024-12
  3. RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT07416474Study sitePhase 3Start 2026-04
  4. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingNCT06890598Study sitePhase 3Start 2025-03
  5. Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung CancerRecruitingNCT06121505Study sitePhase 2Start 2024-03
  6. D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureRecruitingNCT06300177Study sitePhase 3Start 2024-03
  7. YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsNot yet recruitingNCT05767892Study sitePhase 3Start 2023-05
  8. First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon MutationStatus unknownNCT05548348Study sitePhase 2Start 2022-09
  9. Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based ChemotherapyCompletedNCT04447118Study sitePhase 3Start 2020-09
  10. A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung CancerCompletedNCT03594747Study sitePhase 3Start 2018-07
  11. A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung CancerCompletedNCT03663205Study sitePhase 3Start 2018-07

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 23 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
23
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 4420222023: 8820232024: 4420242025: 332025

6 hospitals in Chongqing for pancreatic cancer192 hospitals in China for pancreatic cancer

No open trial on pancreatic cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicineNephrology
Papers it led23
  1. Pancreatic cancer in China: the analysis of cancer mortality and burden in China, 2008-2021.2025BMC cancerFree full text
  2. Assessment of the reliability and quality of pancreatic cancer related short videos on mainstream platforms: cross-sectional study.2025BMC cancerFree full text
  3. Prognostic biomarker MICAL2 and associates with proliferation, migration and immune infiltration in pancreatic adenocarcinoma.2025Journal of applied genetics
  4. US-guided high-intensity focused ultrasound in pancreatic cancer treatment: a consensus initiative between Chinese and European HIFU centers.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  5. Extended lymphadenectomy based on the TRIANGLE for pancreatic head cancer: a single-center experience.2024Langenbeck's archives of surgery
  6. High-Intensity Focused Ultrasound Ablation Combined With Pharmacogenomic-Guided Chemotherapy for Advanced Pancreatic Cancer: Initial Experience.2024Ultrasound in medicine & biology
  7. A novel nomogram based on the number of positive lymph nodes can predict the overall survival of patients with pancreatic head cancer after radical surgery.2024World journal of surgical oncologyFree full text
  8. The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis.2023BMC gastroenterologyFree full text
  9. Research trends and hotspots of neoadjuvant therapy in pancreatic cancer: a bibliometric analysis based on the Web of Science Core Collection.2023Clinical and experimental medicine
  10. Ultra-processed food consumption and the risk of pancreatic cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.2023International journal of cancer
  11. A hybrid nanopharmaceutical for specific-amplifying oxidative stress to initiate a cascade of catalytic therapy for pancreatic cancer.2023Journal of nanobiotechnologyFree full text
  12. Lysyl hydroxylase LH1 promotes confined migration and metastasis of cancer cells by stabilizing Septin2 to enhance actin network.2023Molecular cancerFree full text
  13. The Impact of Bariatric Surgery on Pancreatic Cancer Risk: a Systematic Review and Meta-Analysis.2023Obesity surgery
  14. Plant-based diets and the risk of pancreatic cancer: a large prospective multicenter study.2023The American journal of clinical nutrition
  15. Electrochemiluminescence imaging of a membrane carcinoembryonic antigen at single tissue sections.2023The Analyst
  16. Curcumol inhibits the growth of xenograft-tumors in mice and the biological activities of pancreatic cancer cells by regulating the miR-21-5p/SMAD7 axis.2022Cell cycle (Georgetown, Tex.)Free full text
  17. Double-band ligation-assisted endoscopic submucosal resection for type 1 gastric neuroendocrine tumor with type A gastritis.2022Endoscopy
  18. HTR1D functions as a key target of HOXA10-AS/miR-340-3p axis to promote the malignant outcome of pancreatic cancer via PI3K-AKT signaling pathway.2022International journal of biological sciencesFree full text
  19. Enhanced pentose phosphate pathway activity promotes pancreatic ductal adenocarcinoma progression via activating YAP/MMP1 axis under chronic acidosis.2022International journal of biological sciencesFree full text
  20. Dietary Acid Load and the Risk of Pancreatic Cancer: A Prospective Cohort Study.2021Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  21. Low-carbohydrate diets and the risk of pancreatic cancer: a large prospective cohort study.2021Carcinogenesis
  22. Type 2 diabetes prevention diet and the risk of pancreatic cancer: A large prospective multicenter study.2021Clinical nutrition (Edinburgh, Scotland)
  23. Dietary inflammatory index and pancreatic cancer risk: a systematic review and dose-response meta-analysis.2021Public health nutritionFree full text

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 43 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
43
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 9920212022: 8820222023: 6620232024: 7720242025: 13132025

6 hospitals in Chongqing for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07043725

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou

  2. Recruiting
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06107686

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou

  3. Recruiting
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-06
    Posted
    Registry
    NCT04790305

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineMedical oncologySurgery (general/hepatobiliary/pancreatic)
Papers it led43
  1. Multifunctional ICG-SB@Lip-ZA Nanosystem Focuses on Remodeling the Inflammatory-Immunosuppressive Microenvironment After Photothermal Therapy to Potentiate Cancer Photothermal Immunotherapy.2025Advanced healthcare materials
  2. Gene mutation in cancer patients with diabetes: a real-world retrospective cohort study.2025BMC cancerFree full text
  3. Integrated proteomics and transcriptomics analysis reveals key regulatory genes between ER-positive/PR-positive and ER-positive/PR-negative breast cancer.2025BMC cancerFree full text
  4. Characteristics and prognosis of Her2-negative breast cancer expressing unbalanced hormone receptor.2025BMC women's healthFree full text
  5. MnO2-based nanoparticles remodeling tumor micro-environment to augment sonodynamic immunotherapy against breast cancer.2025Biomaterials science
  6. Trajectories and predictors of financial toxicity in breast cancer patients: A multicenter longitudinal study in China.2025Breast (Edinburgh, Scotland)Free full text
  7. Association between radiotherapy and the risk of second primary malignancies in breast cancer patients with different estrogen receptor statuses.2025European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  8. Loss of RPN1 promotes antitumor immunity via PD-L1 checkpoint blockade in triple-negative breast cancer - experimental studies.2025International journal of surgery (London, England)
  9. Large Language Models as a Consulting Hotline for Patients With Breast Cancer and Specialists in China: Cross-Sectional Questionnaire Study.2025JMIR medical informaticsFree full text
  10. GLUTs-Facilitated Targeting BRD4 Degradation in Breast Cancer through Carbohydrate-Conjugated PROTACs.2025Journal of medicinal chemistry
  11. RPL17 regulates the progression of breast cancer accompanied by MAPK signaling activation.2025Medical oncology (Northwood, London, England)
  12. A PTT-Induced Feed-Back Carbon Nanosystem for Enhanced Breast Cancer Therapy by Extracellular Matrix Remodeling.2025Nano letters
  13. Unraveling the vicious cycle: longitudinal analysis between financial toxicity and symptom burden in women with breast cancer.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  14. Combination of MHI148 Targeted Photodynamic Therapy and STING Activation Inhibits Tumor Metastasis and Recurrence.2024ACS applied materials & interfaces
  15. Epoxy metabolites of linoleic acid promote the development of breast cancer via orchestrating PLEC/NFκB1/CXCL9-mediated tumor growth and metastasis.2024Cell death & diseaseFree full text
  16. LIFU/MMP-2 dual-responsive release of repurposed drug disulfiram from nanodroplets for inhibiting vasculogenic mimicry and lung metastasis in triple-negative breast cancer.2024Journal of nanobiotechnologyFree full text
  17. Nitric oxide nano-reactor DNMF/PLGA enables tumor vascular microenvironment and chemo-hyperthermia synergetic therapy.2024Journal of nanobiotechnologyFree full text
  18. Application of fluorocarbon nanoparticles of 131I-fulvestrant as a targeted radiation drug for endocrine therapy on human breast cancer.2024Journal of nanobiotechnologyFree full text
  19. Metal-ion-chelating phenylalanine nanostructures reverse immune dysfunction and sensitize breast tumour to immune checkpoint blockade.2024Nature nanotechnology
  20. Prediction of non-sentinel lymph node metastases in T1-2 sentinel lymph node-positive breast cancer patients undergoing mastectomy following neoadjuvant therapy.2024World journal of surgical oncologyFree full text
  21. Engineered Biomimetic Copper Sulfide Nanozyme Mediates "Don't Eat Me" Signaling for Photothermal and Chemodynamic Precision Therapies of Breast Cancer.2023ACS applied materials & interfaces
  22. Nickel-Doped Microfluidic Chip for Rapid and Efficient Immunomagnetic Separation and Detection of Breast Cancer Cell-Derived Exosomes.2023Applied biochemistry and biotechnology
  23. A multi-dimensional nomogram to predict non-sentinel lymph node metastases in T1-2HR+ breast cancer.2023Frontiers in endocrinologyFree full text
  24. Assessment of the reliability and quality of breast cancer related videos on TikTok and Bilibili: cross-sectional study in China.2023Frontiers in public healthFree full text
  25. Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer.2023Frontiers in public healthFree full text
  26. IGJ suppresses breast cancer growth and metastasis by inhibiting EMT via the NF‑κB signaling pathway.2023International journal of oncologyFree full text
  27. DCE-MRI Performance in Triple Negative Breast Cancers: Comparison with Non-Triple Negative Breast Cancers.2022Current medical imaging
  28. Free triiodothyronine and free thyroxine hormone levels in relation to breast cancer risk: a meta-analysis.2022Endokrynologia Polska
  29. Nomogram models for stratified prediction of axillary lymph node metastasis in breast cancer patients (cN0).2022Frontiers in endocrinologyFree full text
  30. Identifying and Validating of an Autophagy-Related Gene Signature for the Prediction of Early Relapse in Breast Cancer.2022Frontiers in endocrinologyFree full text
  31. miR‑382 inhibits breast cancer progression and metastasis by affecting the M2 polarization of tumor‑associated macrophages by targeting PGC‑1α.2022International journal of oncologyFree full text
  32. Experiment research on the treatment of sevoflurane to human breast cancer cell with high intensity focused ultrasound.2022Panminerva medica
  33. Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study.2022The breast journalFree full text
  34. Combating multidrug resistance and metastasis of breast cancer by endoplasmic reticulum stress and cell-nucleus penetration enhanced immunochemotherapy.2022TheranosticsFree full text
  35. Biomimetic "Nanoplatelets" as a Targeted Drug Delivery Platform for Breast Cancer Theranostics.2021ACS applied materials & interfaces
  36. Perfluorocarbon Nanodroplets with Deep Tumor Penetration and Controlled Drug Delivery for Ultrasound/Fluorescence Imaging Guided Breast Cancer Therapy.2021ACS biomaterials science & engineering
  37. Bioinformatic Analysis of Immune Significance of RYR2 Mutation in Breast Cancer.2021BioMed research internationalFree full text
  38. Significant difference between coagulation parameters and clinicopathological characteristics in breast cancer.2021Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  39. Cancer-Specific Survival Outcome in Early-Stage Young Breast Cancer: Evidence From the SEER Database Analysis.2021Frontiers in endocrinologyFree full text
  40. Risk Factors, Prognostic Factors, and Nomogram for Distant Metastasis in Breast Cancer Patients Without Lymph Node Metastasis.2021Frontiers in endocrinologyFree full text
  41. A Novel Immune and Stroma Related Prognostic Marker for Invasive Breast Cancer in Tumor Microenvironment: A TCGA Based Study.2021Frontiers in endocrinologyFree full text
  42. Overexpression of IL-8 promotes cell migration via PI3K-Akt signaling pathway and EMT in triple-negative breast cancer.2021Pathology, research and practice
  43. Increased photodynamic therapy sensitization in tumors using a nitric oxide-based nanoplatform with ATP-production blocking capability.2021TheranosticsFree full text
All its trials on ClinicalTrials.gov, any status4
  1. A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerRecruitingNCT07043725Study sitePhase 3Start 2025-09
  2. A Study of YL202 in Selected Patients With Advanced Solid TumorsRecruitingNCT06107686Study sitePhase 2Start 2023-12
  3. Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast CancerRecruitingNCT04790305Study sitePhase 4Start 2021-06
  4. A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Active, not recruitingNCT06680921Study sitePhase 3Start 2024-11

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 18 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.2%.

Papers led
18
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 5520232024: 7720242025: 332025

8 hospitals in Chongqing for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led18
  1. Nanoparticle-based drug delivery systems to modulate tumor immune response for glioblastoma treatment.2025Acta biomaterialia
  2. Establishment and validation of a recurrent prediction model for glioma: extrinsic apoptotic molecules FADD and CASP8 are closely associated with glioma recurrence.2025BMC immunologyFree full text
  3. P4HA1 mediates YAP hydroxylation and accelerates collagen synthesis in temozolomide-resistant glioblastoma.2025Chinese medical journalFree full text
  4. Bioinspired Lipoproteins of Furoxans-Gemcitabine Preferentially Targets Glioblastoma and Overcomes Radiotherapy Resistance.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. Glioma-derived S100A9 polarizes M2 microglia to inhibit CD8+T lymphocytes for immunosuppression via αvβ3 integrin/AKT1/TGFβ1.2024Biochimica et biophysica acta. Molecular cell research
  6. PTPN7 mediates macrophage-polarization and determines immunotherapy in gliomas: A single-cell sequencing analysis.2024Environmental toxicology
  7. The effect Of vascular related CeRNA genes and corresponding imaging biomarkers on survival in lower grade glioma.2024Irish journal of medical science
  8. Orexin-A mediates glioblastoma proliferation inhibition by increasing ferroptosis triggered by unstable iron pools and GPX4 depletion.2024Journal of cellular and molecular medicineFree full text
  9. To editor: "The role of postoperative blood pressure management in early postoperative hemorrhage in awake craniotomy glioma patients".2024Neurosurgical review
  10. To editor: "T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant".2024Neurosurgical review
  11. Allomelanin-based biomimetic nanotherapeutics for orthotopic glioblastoma targeted photothermal immunotherapy.2023Acta biomaterialia
  12. Hypocretin-1 suppresses malignant progression of glioblastoma cells through Notch1 signaling pathway.2023Brain research bulletin
  13. Exosome-based nanoimmunotherapy targeting TAMs, a promising strategy for glioma.2023Cell death & diseaseFree full text
  14. RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis.2023Frontiers in immunologyFree full text
  15. D-2-hydroxyglutarate regulates human brain vascular endothelial cell proliferation and barrier function.2023Journal of neuropathology and experimental neurologyFree full text
  16. The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial.2022TrialsFree full text
  17. Self-Assembled DNA Nanostructure as a Carrier for Targeted siRNA Delivery in Glioma Cells.2021International journal of nanomedicineFree full text
  18. Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound.2021International journal of nanomedicineFree full text

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 5 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 1.7%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 1120242025: 112025

6 hospitals in Chongqing for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 7 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 442025

19 hospitals in Chongqing for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicinePediatrics

Over half of these papers are lab or animal studies.

Papers it led7
  1. Protein Kinase Inhibitor Alpha Drives Vincristine Resistance in Ewing Sarcoma via cAMP-EPAC Signaling Reprogramming.2026Molecular carcinogenesis
  2. Genetically Engineered Glycosylphosphatidylinositol-Anchored Anti-GD2 Nanobody-Exosome Mimetics for Targeted Osteosarcoma Therapy In Vitro and In Vivo.2025ACS applied materials & interfaces
  3. An "Outer Piezoelectric and Inner Epigenetic" Logic-Gated PANoptosis for Osteosarcoma Sono-Immunotherapy and Bone Regeneration.2025Advanced materials (Deerfield Beach, Fla.)
  4. Structural characteristics of a fructan-type polysaccharide from Asparagus cochinchinensis rhizome and its anti-osteosarcoma activity mediated via macrophage polarization.2025International journal of biological macromolecules
  5. DCC-2036 inhibits osteosarcoma via targeting HCK and the PI3K/AKT-mTORC1 axis to promote autophagy.2025World journal of surgical oncologyFree full text
  6. FOSL1 promotes stem cell‑like characteristics and anoikis resistance to facilitate tumorigenesis and metastasis in osteosarcoma by targeting SOX2.2024International journal of molecular medicineFree full text
  7. Advances on immunotherapy for osteosarcoma.2024Molecular cancerFree full text
Earlier papers (2016–2020)6
  1. A meta-analysis of prognostic factors of osteosarcoma.2020European review for medical and pharmacological sciences
  2. Multifunctional bone cement for synergistic magnetic hyperthermia ablation and chemotherapy of osteosarcoma.2020Materials science & engineering. C, Materials for biological applications
  3. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo.2019Environmental health and preventive medicine
  4. Efficacy Comparison of Six Chemotherapeutic Combinations for Osteosarcoma and Ewing's Sarcoma Treatment: A Network Meta-Analysis.2018Journal of cellular biochemistry
  5. miR‑494 inhibits cell proliferation and metastasis via targeting of CDK6 in osteosarcoma.2017Molecular medicine reports
  6. Tetrandrine inhibits the proliferation of human osteosarcoma cells by upregulating the PTEN pathway.2017Oncology reports

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 4 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 222025

10 hospitals in Chongqing for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

10 hospitals in Chongqing for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Chongqing for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

4 hospitals in Chongqing for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunosuppressive treatment

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

4 hospitals in Chongqing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics & inherited formsDiagnosis & prognosis

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Chongqing for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 2 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 3.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

3 hospitals in Chongqing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Chongqing for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 10 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.2%.

Papers led
10
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 1120232024: 3320242025: 112025

7 hospitals in Chongqing for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    Phase
    N/A
    Started
    2021-09
    Posted
    Registry
    NCT04995159

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led10
  1. From sweetener to risk factor: Network toxicology, molecular docking and molecular dynamics reveal the mechanism of aspartame in promoting coronary heart disease.2026Chemico-biological interactions
  2. Multi-Omic Insight Into the Molecular Networks in the Pathogenesis of Coronary Artery Disease.2025Journal of the American Heart AssociationFree full text
  3. Wellen's syndrome caused by severe ostial stenosis of the left main coronary artery: a case report.2024BMC cardiovascular disordersFree full text
  4. Letter to the editor: Drug-coated balloon angioplasty versus drug-eluting stent implantation in ACS patients with different angiographic patterns of in-stent restenosis.2024International journal of cardiology
  5. Body Mass Index and All-Cause Mortality in Elderly Patients with Percutaneous Coronary Intervention: A Meta-Analysis.2024Obesity factsFree full text
  6. Relationship between Parkinson's disease and cardio-cerebrovascular diseases: a Mendelian randomized study.2023Scientific reportsRCTFree full text
  7. Do plaque-related factors affect the diagnostic performance of an artificial intelligence coronary-assisted diagnosis system? Comparison with invasive coronary angiography.2022European radiology
  8. Correlation between plasma sphingosine-1-phosphate and the occurrence and severity of coronary heart disease in postmenopausal women.2022Menopause (New York, N.Y.)
  9. Performance of artificial intelligence-based coronary artery calcium scoring in non-gated chest CT.2021European journal of radiology
  10. The effects of lipid-lowering therapy on coronary plaque regression: a systematic review and meta-analysis.2021Scientific reportsFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Positive Association of US-FLI With the Severity of CADStatus unknownNCT06541132Lead (inferred)Start 2022-07
  2. Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS SystemNot yet recruitingNCT04995159Study siteN/AStart 2021-09
  3. Efficacy and Safety of Colchicine After PCIActive, not recruitingNCT06472908Study sitePhase 3Start 2024-07
  4. Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast MediumCompletedNCT03671603Study siteStart 2018-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 4 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 002025

7 hospitals in Chongqing for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Chongqing for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led 1 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Chongqing for hepatic echinococcosis44 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Chongqing for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

6 hospitals in Chongqing for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

7 hospitals in Chongqing for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

13 hospitals in Chongqing for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Metabolomics study reveals blood biomarkers for early diagnosis of chronic kidney disease and IgA nephropathy: A retrospective cross-sectional study.2024Clinica chimica acta; international journal of clinical chemistry
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Niemann–Pick disease type C

尼曼-匹克病 C 型

Led 1 of the 16 English-language PubMed papers on Niemann–Pick disease type C with an author in mainland China, 2021–2025: 6.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Chongqing for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C

No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution

5 hospitals in Chongqing for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  2. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Earlier papers (2016–2020)2
  1. [Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  2. [Meta-analysis of anti-GP210 antibody and anti-SP100 antibody detection for diagnosis of primary biliary cirrhosis].2016Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
All its trials on ClinicalTrials.gov, any status2
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  2. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

重庆医科大学附属第二医院

Second Affiliated Hospital of Chongqing Medical University

重庆

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Second Affiliated Hospital of Chongqing Medical Univerity; Second Affiliated Hospital of Chongqing Medical; Second affiliated hospital of Chongqing Medical University; he Second Affiliated Hospital of Chongqing Medical University

Suggest a correctionDownload the data